Model Answer

Recent advances in antiviral pharmacology have shifted from targeting only viral enzymes to attacking structural components of viruses. In this context, capsid-targeting therapy for Human Immunodeficiency Virus (HIV), especially long-acting drugs such as lenacapavir, marks a significant breakthrough in both treatment and prevention strategies.

1. HIV Capsid as a Drug Target

The HIV virus consists of genetic material (RNA), enzymes, and a protective protein shell called the capsid. Traditionally, antiretroviral therapy (ART) targeted viral enzymes such as reverse transcriptase, protease, and integrase. However, the capsid has emerged as a superior target due to several reasons:

Essential for viral survival – The capsid protects viral RNA and regulates entry into host cells.

Controls replication cycle – It plays a role in transport to the nucleus and release of genetic material.

Structurally fragile – Even small disturbances destabilize viral functioning.

Thus, interfering with the capsid disrupts multiple stages of the viral life cycle rather than a single step.

2. Significance of Lenacapavir and Long-Acting Therapy

Lenacapavir is the first capsid inhibitor designed as a long-acting injectable drug given once every six months. Its importance lies in both clinical and public-health dimensions.

(a) Medical Advantages

Blocks HIV replication at multiple stages simultaneously.

Effective even in drug-resistant HIV cases.

Improves treatment adherence compared to daily pills.

Reduces viral load sustainably.

(b) Preventive Potential

Clinical trials showed extremely high protection in high-risk individuals, indicating potential use in pre-exposure prophylaxis (PrEP).

(c) Public Health Impact

Beneficial for populations with poor healthcare access.

Reduces transmission chains.

Helps achieve global HIV elimination targets.

Thus, long-acting therapy shifts HIV management from daily compliance-dependent treatment to periodic prevention-oriented healthcare.

3. Challenge of Drug Resistance

Viruses evolve rapidly. HIV can develop mutations that reduce susceptibility to lenacapavir, especially when used alone (monotherapy).

However, research reveals an important phenomenon:

Resistance mutations weaken the virus’s ability to replicate (fitness cost).

Drug-resistant variants spread poorly compared to normal HIV.

This indicates capsid targeting forces the virus into an evolutionary trade-off — survival vs replication efficiency.

4. Role of Combination Therapy

To prevent resistance, modern HIV treatment follows combination antiretroviral therapy (cART).

Why combination therapy is necessary:

Reduces probability of multiple simultaneous mutations.

Maintains sustained viral suppression.

Prevents treatment failure.

Limits transmission of resistant strains.

Therefore, lenacapavir is most effective when integrated into multi-drug regimens rather than used alone.

Capsid-targeting therapies such as lenacapavir represent a paradigm shift in HIV management by combining treatment and prevention in a long-acting format. While drug resistance remains a challenge, the reduced fitness of resistant viruses and use of combination therapy make this approach highly promising. Beyond HIV, it signals the future of antiviral medicine — targeting fundamental viral structures to achieve durable and scalable disease control.